The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer

Authors: ODwyer M.E.; Druker B.J.

Source: Current Cancer Drug Targets, Volume 1, Number 1, May 2001 , pp. 49-57(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.

Keywords: Tyrosine Kinase Inhibitor; myelogenous leukaemia; Ph chromosome; allogeneic stem cell; optimal anti-leukemic effects; myelosuppression; CML blast crisis; Bcr-Abl associated leukemias; chronic myelomonocytic leukemic

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568009013334250

Publication date: 2001-05-01

More about this publication?

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.